Clinical trial

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

NCT01490632

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-12-01

PhasePHASE2

Study timeline

Study start (unknown)2011-12-01Date precision: month

Registry last updated2019-09-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Psoriasisunresolved

Skin Diseasesunresolved

Skin Diseases, Papulosquamousunresolved

Interventions

PlaceboDRUG

BaricitinibDRUG · verified · RxNorm: baricitinib

Sponsors & collaborators

Eli Lilly and Companylead sponsor

Incyte Corporationcollaborator

Mapped research locations

PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 MiamiFlorida, United States1 SeattleWashington, United States1 AustinTexas, United States1 RochesterNew York, United States1 Salt Lake CityUtah, United States1 Winston-SalemNorth Carolina, United States1 LouisvilleKentucky, United States1 AlbuquerqueNew Mexico, United States1 TokyoJapan1 OsakaJapan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01490632 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.